UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 93

Sortiert nach

Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

Annals of oncology, 2006-05, Vol.17 (5), p.813-817

2006

Volltextzugriff (PDF)

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

Journal of clinical oncology, 1998-10, Vol.16 (10), p.3362-3368

1998

Volltextzugriff (PDF)

Management of Breast Cancer During Pregnancy Using a Standardized Protocol

Journal of clinical oncology, 1999-03, Vol.17 (3), p.855-861

1999

Volltextzugriff (PDF)

Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience

Journal of clinical oncology, 2001-02, Vol.19 (3), p.628-633

2001

Volltextzugriff (PDF)

Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3412-3417

1999

Volltextzugriff (PDF)

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

Journal of clinical oncology, 1996-10, Vol.14 (10), p.2713-2721

1996

Volltextzugriff (PDF)

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

JNCI : Journal of the National Cancer Institute, 2000-02, Vol.92 (3), p.225-233

2000

Volltextzugriff (PDF)

Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations

Annals of oncology, 2008-10, Vol.19 (10), p.1713-1719

2008

Volltextzugriff (PDF)

Anthracycline antibiotics in cancer therapy : focus on drug resistance

Drugs (New York, N.Y.), 1994-02, Vol.47 (2), p.223-258

1994

Volltextzugriff (PDF)

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

Clinical & experimental metastasis, 2013-06, Vol.30 (5), p.631-642

2013

Volltextzugriff (PDF)

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results

Annals of oncology, 1999-04, Vol.10 (4), p.403-411

1999

Volltextzugriff (PDF)

Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

Cancer, 2005-05, Vol.103 (9), p.1763-1769

2005

Volltextzugriff (PDF)

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5983-5992

2005

Volltextzugriff (PDF)

Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer : A phase II study

American journal of clinical oncology, 2000-02, Vol.23 (1), p.40-41

2000

Volltextzugriff (PDF)

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience

Surgical oncology clinics of North America, 1995-10, Vol.4 (4), p.715-734

1995

Volltextzugriff (PDF)

Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer

Journal of clinical oncology, 1994-01, Vol.12 (1), p.50-54

1994

Volltextzugriff (PDF)

Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer

American journal of clinical oncology, 2000-04, Vol.23 (2), p.117-121

2000

Volltextzugriff (PDF)

CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark

Breast diseases, 2011-01, Vol.22 (3), p.298-299

Booser, D.J.

2011

Volltextzugriff (PDF)

Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer

Journal of immunotherapy with emphasis on tumor immunology, 1995-10, Vol.18 (3), p.185

1995

Volltextzugriff (PDF)

Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369–377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer

Clinical cancer research, 2002-11, Vol.8 (11), p.3407-3418

2002

Volltextzugriff (PDF)

Capecitabine in operable triple receptor–negative breast cancer: A subgroup analysis of a randomized phase III trial

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.292-292

2011

Volltextzugriff (PDF)

Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial

Clinical cancer research, 2002-05, Vol.8 (5), p.1073-1079

2002

Volltextzugriff (PDF)

Phase I study of liposomal annamycin

Cancer chemotherapy and pharmacology, 2000, Vol.46 (5), p.427-432

2000

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(87)

Publikationsform

Artikel
(91)
Bücher
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(53)
Life Sciences & Biomedicine
(50)
Science & Technology
(50)
Female
(48)
Oncology
(47)
Middle Aged
(45)
Adult
(42)
Biological And Medical Sciences
(41)
Medical Sciences
(41)
Aged
(38)
Breast Neoplasms - Drug Therapy
(34)
Pharmacology. Drug Treatments
(33)
Antineoplastic Agents
(32)
Chemotherapy
(29)
Breast Neoplasms - Pathology
(28)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(23)
Doxorubicin - Administration & Dosage
(17)
Male
(14)
Treatment Outcome
(14)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

Management of Breast Cancer During Pregnancy Using a Standardized Protocol

Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience

Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

Imatinib mesylate (Gleevec®) in advanced breast cancer-expressing C-Kit or PDGFR-β: clinical activity and biological correlations

Anthracycline antibiotics in cancer therapy : focus on drug resistance

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results

Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer : A phase II study

Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience

Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer

Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer

CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer

Toxicity, Immunogenicity, and Induction of E75-specific Tumor-lytic CTLs by HER-2 Peptide E75 (369–377) Combined with Granulocyte Macrophage Colony-stimulating Factor in HLA-A2+ Patients with Metastatic Breast and Ovarian Cancer

Capecitabine in operable triple receptor–negative breast cancer: A subgroup analysis of a randomized phase III trial

Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial

Phase I study of liposomal annamycin

Suchergebnisse filtern